What's Happening?
Sandoz, the former generics and biosimilars arm of Novartis, has unveiled its ambitious 'Bio100' growth plan, aiming to significantly expand its biosimilars portfolio to over 100 products, including generic GLP-1s, by 2040. The company also plans to more
than double its net sales by 2035 and increase its manufacturing capacity. Currently, biosimilars account for 30% of Sandoz's revenues, with 13 biosimilars in its commercial portfolio. The Bio100 plan seeks to capitalize on the projected loss of exclusivity (LoE) for innovator biologics, which is estimated to create over $300 billion in market opportunities between 2026 and 2040. Sandoz expects to increase its biosimilar LoE value coverage to over 80% by 2035 and 2040, up from 50% currently, and aims for a core EBITDA margin above 30% by 2035. The company is also increasing its in-house biosimilar development from approximately two per year to up to ten per year by 2040.
Why It's Important?
Sandoz's Bio100 plan holds significant implications for the U.S. pharmaceutical market, particularly in terms of drug affordability and patient access. The expansion of its biosimilars portfolio, including generic GLP-1s, will introduce more cost-effective alternatives to expensive biologic drugs. This increased competition is expected to drive down healthcare costs for patients, insurance providers, and the U.S. healthcare system as a whole. Biosimilars offer similar efficacy and safety profiles to their reference biologics but at a lower price point, making advanced treatments more accessible for chronic conditions like diabetes, obesity, and various autoimmune diseases. The plan's focus on capturing a larger share of the LoE market opportunities means that more U.S. patients will have access to affordable versions of critical medications as patents expire, potentially improving health outcomes and reducing financial burdens.
What's Next?
Sandoz is investing over EUR 1.0 billion ($1.12 billion) to establish a biosimilars manufacturing hub in Europe, with vertical integration across development and manufacturing. Key expansions include a $300 million investment in a new biologics drug-substance production facility in Ljubljana, Slovenia, operational by 2029, and a $440 million sterile drug-product manufacturing facility in Brnik, operational by 2028. The company also completed the acquisition of Just-Evotec Biologics EU SAS in late 2025, adding a site in Toulouse, France, for small-scale continuous biomanufacturing. These investments aim to shift Sandoz's reliance from contract development and manufacturing organizations (CDMOs) to approximately 60% in-house manufacturing and 50-70% in-house development. This strategic move will enhance Sandoz's control over its supply chain, ensuring more reliable and cost-effective production of biosimilars for global markets, including the U.S.
Beyond the Headlines
The aggressive expansion of Sandoz into the biosimilars market, particularly with generic GLP-1s, could trigger a significant transformation in the U.S. pharmaceutical landscape. The influx of affordable biosimilars will not only challenge the pricing power of innovator biologic manufacturers but also accelerate the adoption of biosimilars by healthcare providers and patients. This shift could lead to a re-evaluation of prescribing practices and formulary decisions, prioritizing cost-effectiveness without compromising clinical outcomes. Furthermore, the increased competition could spur further innovation in the biologics space, as innovator companies strive to differentiate their products. The long-term impact could be a more sustainable and equitable healthcare system in the U.S., where advanced treatments are not solely dictated by their high price tags, but by their clinical value and accessibility to a broader population.
